ROLE SUMMARY
Growth hormone deficiency is a rare disease characterized by the inadequate secretion of growth hormone from the pituitary gland. It affects one in approximately 4,000 to 10,000 people. Somatrogon (a Long Acting Growth Hormone, requiring once weekly injection) represents a significant innovation from the current standard of care of a once-daily injection. If approved, somatrogon could reduce the daily disease burden on children and their caregivers, potentially increasing treatment adherence. Somatogon is expected to launch in Q4 2021 in the US, followed by Japan, EU and select ROW markets in S1 2022.
The Director, Global Marketing, Somatrogon HCP Customer Lead role will oversee the strategy, development, and execution of the global core HCP branded campaign and associated assets during an exciting time of preparation for a 2021 launch. Key HCP branded assets include the HCP campaign concept finalization, the white paper, visual aid, digital resources and toolkits, etc. The Somatrogon HCP Customer Lead will be responsible for developing assets in a Glocal model, engaging markets throughout the development process, incorporating feedback, and conducting global read-outs to ensure a common global understanding of the strategy driving the final deliverable, as well as timing for delivery to the markets. This individual will also partner closely with the US team (as the first market to launch) on creative content, to ensure that the US team receives global resources in a timely fashion to support launch and the creation of downstream US specific tactics. Finally, additional responsibilities include those closely associated with HCP branded content development and US liaison responsibilities, such as market research related efforts.
This individual will report directly into the VP, Global Inline Brands, but with a dotted line to the Somatrogon Launch Lead. This individual will not have direct reporting responsibilities but will oversee work efforts across a cross-functional team.
Global Marketing
* Lead development of core HCP branded marketing materials, serving as the agency of record point of contact to provide strategic guidance, oversight and direction to the creation of glocal creative materials
* Ensure glocal development, via solicitation of country feedback and incorporation of country feedback / needs into development efforts, where appropriate
* Ensure understanding of synergies between core HCP brand materials, and US (first market to launch) materials
* Develop and execute a strategy to leverage select, best practice materials from specific markets for global use, where relevant
* Manage the agency of record
* Serve as the global marketing team packaging lead, ensuring delivery and approval of packaging materials in conjunction with packaging cross-functional partners
* Develop global somatrogon field training strategy and materials in partnership with the training team
BASIC QUALIFICATIONS
* BA/BS - degree required. Advance degree preferred
* 10 years of pharmaceutical industry experience in marketing, strategy, and/or new product launch in pharmaceutical, medical device or biotechnology companies
* Global or regional marketing experience preferred
* Demonstrated strong project management skills
* Self-starter who can multitask in a fast-paced and dynamic environment
* Strategic cross functional leadership experience
* Proven management and leadership skills in a cross functional, matrix environment; ability to lead by influence & example to effectively implement strategies with internal/external stakeholders
* Change-agile business driver able to motivate cross functional team members without direct oversight or reporting responsibility
* Strong communication skills, ability to infuse enthusiasm, energy, confidence into teams
* Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.Relocation support available
Other Job Details:
* Last Date to Apply for Job: March 22, 2021
* Additional Location Information: Potential for travel up to 30%
* Eligible for Relocation Package
Sunshine Act
Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care providers name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.
EEO & Employment Eligibility
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.
Marketing and Market Research
LI-PFE
New York, New York
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names.
Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Pfizer, Merck & Co., Inc., and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.